LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

Search

Avita Therapeutics Inc

Open

3.43

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.34

Max

3.48

Schlüsselkennzahlen

By Trading Economics

Einkommen

-3.3M

-13M

Verkäufe

-1.4M

17M

EPS

-0.712

Gewinnspanne

-77.289

Angestellte

260

EBITDA

4M

-8.1M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+93.45% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-17M

104M

Vorheriger Eröffnungskurs

3.43

Vorheriger Schlusskurs

3.43

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Avita Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Dez. 2025, 23:54 UTC

Heiße Aktien

Stocks to Watch: Nike, Cassava Sciences, KB Home

18. Dez. 2025, 23:51 UTC

Ergebnisse

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18. Dez. 2025, 23:39 UTC

Wichtige Markttreiber

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18. Dez. 2025, 22:57 UTC

Akquisitionen, Fusionen, Übernahmen

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18. Dez. 2025, 21:40 UTC

Ergebnisse

Nike Sales Tick Up, But China Weakness Persists

18. Dez. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18. Dez. 2025, 23:37 UTC

Market Talk
Ergebnisse

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18. Dez. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18. Dez. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18. Dez. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18. Dez. 2025, 23:00 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18. Dez. 2025, 22:59 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18. Dez. 2025, 22:58 UTC

Akquisitionen, Fusionen, Übernahmen

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18. Dez. 2025, 22:57 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18. Dez. 2025, 22:56 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18. Dez. 2025, 22:55 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:59 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Dez. 2025, 21:35 UTC

Ergebnisse

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18. Dez. 2025, 21:31 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Greater China Rev Down 17% >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q EPS 53c >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Apparel Rev $3.91B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Equipment Rev $550M >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q N Amer Rev $5.63B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Footwear Rev $7.66B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Greater China Rev $1.42B >NKE

Peer-Vergleich

Kursveränderung

Avita Therapeutics Inc Prognose

Kursziel

By TipRanks

93.45% Vorteil

12-Monats-Prognose

Durchschnitt 6.5 USD  93.45%

Hoch 11 USD

Tief 3 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Avita Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

2

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

8.83 / 9.77Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
help-icon Live chat